NCT07060287 is a clinical trial of Clock-Guided Minimally Invasive Surgery in Pulmonary Nodule Cm, sponsored by The First Hospital of Hebei Medical University.

Who is sponsoring NCT07060287?

NCT07060287 is sponsored by The First Hospital of Hebei Medical University.

What drugs are being tested in NCT07060287?

Interventions in NCT07060287: Clock-Guided Minimally Invasive Surgery.

What condition does NCT07060287 study?

NCT07060287 studies Pulmonary Nodule Cm.

Is NCT07060287 still recruiting?

NCT07060287 is currently completed. Last updated 11 July 2025.

Last reviewed 2025-07-11 · How we verify

NCT07060287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Value of miR-21 and miR-486 in Pulmonary Nodule Surgery

Completed Last updated 11 July 2025

What this trial tests

trial testing Clock-Guided Minimally Invasive Surgery in Pulmonary Nodule Cm in 138 participants. Completed in 1 January 2022.

Timeline

1 January 2020

Primary endpoint
1 January 2022

1 January 2022

Quick facts

Lead sponsor	The First Hospital of Hebei Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	138
Start date	1 January 2020
Primary completion	1 January 2022
Estimated completion	1 January 2022
Sites	1 location across China

Drugs / interventions tested

Clock-Guided Minimally Invasive Surgery

Conditions studied

Pulmonary Nodule Cm — all drugs for Pulmonary Nodule Cm →

Sponsor

The First Hospital of Hebei Medical University

Who can join

18 and older, any sex, with Pulmonary Nodule Cm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study prospectively evaluated the prognostic value of microRNA-21 (miR-21) and microRNA-486 (miR-486) expression in patients with pulmonary nodules who underwent clock-guided minimally invasive surgery. The study aimed to determine if high expression levels of these miRNAs in resected nodule tissue correlate with poorer clinical outcomes, including larger residual tumor size, higher metabolic activity, and shorter overall and progression-free survival.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other The First Hospital of Hebei Medical University trials

Trials by the same sponsor.

NCT07467603 — ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients · NA · completed
NCT07243444 — Home-Based Versus Center-Based Cardiac Rehabilitation After CABG Surgery · NA · completed
NCT07047534 — EEG-Triggered rTMS and Group Therapy for Adolescents With Depression and Self-Harm · NA · completed
NCT07232693 — Telerehabilitation vs. Center-Based Rehab for Psychological Well-being After CABG · NA · completed
NCT06344390 — Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07060287 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Hebei Medical University
Last refreshed: 11 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07060287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing